Is AbCellera Biologics (ABCL) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 01/03/24
AbCellera to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024Business Wire • 12/20/23
Buy AbCellera Biologics's Revolutionizing AI-Powered Drug Development PlatformSeeking Alpha • 12/08/23
AbCellera to Present at the Piper Sandler 35th Annual Healthcare Conference on November 30, 2023Business Wire • 11/16/23
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in OncologyBusiness Wire • 11/01/23
AbCellera to Present at the Jefferies London Healthcare Conference on November 14, 2023Business Wire • 10/31/23
Earnings Preview: AbCellera Biologics Inc. (ABCL) Q3 Earnings Expected to DeclineZacks Investment Research • 10/26/23
AbCellera Expands Multi-Target Antibody Discovery Collaboration with RegeneronBusiness Wire • 09/20/23
AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in OncologyBusiness Wire • 09/13/23
AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/03/23
Does AbCellera Biologics Inc. (ABCL) Have the Potential to Rally 242.09% as Wall Street Analysts Expect?Zacks Investment Research • 07/25/23
AbCellera Announces that the U.S. Patent Trial and Appeal Board Has Denied Berkeley Lights' Request for RehearingBusiness Wire • 07/24/23
Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCelleraBusiness Wire • 06/15/23